Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Gene Silencing/Gene Editing » Melvin Rubin, Pascal Goldschmidt

Melvin Rubin, Pascal Goldschmidt

Oct 04, 2007
Premium
Opko Health said last month in a filing with the US Securities and Exchange Commission that Melvin Rubin has resigned as a member of its board.
 
The resignation did not arise from any disagreement with the company, Opko said.
 
This week, Opko said that Pascal Goldschmidt has joined its board, filling the vacancy left by Rubin.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Plans Out

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

CovidNudge Numbers

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

Science Papers Propose Group to Discuss Genome-Editing Tools, Markers of Diabetes Drug Response, More

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

Not Counting These

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Oct
28
Featured Webinar

How Low Can You Go? Reduce Breeding Costs with an Optimized Genotyping and Analysis Strategy

Sponsored by
NRGene

Molecular breeding methods such as genomic selection and genome-wide association studies often require high-density genotypic data from many samples, but the cost and complexity of genotyping at this scale may be prohibitive.

What's Popular?

In Gene Silencing/Gene Editing

  1. JumpCode Genomics Emerges From Stealth Mode With CRISPR-Based Library Prep Kits

    Premium

  2. CRISPR-Chip Maker Cardea Bio Raises $7.5M in First Close of Series A2 Financing Round

  3. Startup Stitch Bio Bets on CRISPR Tech to Render Cancer Cells With Gene Fusions Druggable

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.